Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384206 | 0.85 | ALDH1A1 (0.52) | HTR1AKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL23164620 | 0.84 | HTR1A (0.67) | HTR1A | |
| SCHEMBL12332512 | 0.84 | HTR1A (0.67) | HTR1A | |
| SCHEMBL29564155 | 0.80 | HTR1A (0.55) | HTR1A | |
| SCHEMBL20404 | 0.80 | HTR1A (0.55) | HTR1A | |
| SCHEMBL8556230 | 0.78 | GRM5 (0.66) | HTR1AKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL30249433 | 0.78 | HTR1A (0.64) | HTR1AALDH1A1 | |
| SCHEMBL6954706 | 0.78 | HTR1A (0.64) | HTR1AALDH1A1 | |
| SCHEMBL29163908 | 0.77 | ALDH1A1 (0.66) | HTR1AALDH1A1RAB9APOLB | |
| SCHEMBL30690126 | 0.77 | ALDH1A1 (0.66) | HTR1AALDH1A1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-10953095-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-03-23 | — | — | US | disclosed |
| US-20200138955-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-05-07 | — | — | US | disclosed |
| US-10456473-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-29 | — | — | US | disclosed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
| US-9694077-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9694077-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-04 | — | — | US | disclosed |
| EP-3097908-A1 | LIPID COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2016-11-30 | — | — | EP | disclosed |
| US-20150190515-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2015-07-09 | — | — | US | disclosed |
| US-20150190515-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2015-07-09 | — | — | US | disclosed |
| US-8883202-B2 | Lipid compositions | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-11-11 | — | — | US | disclosed |
| US-8883202-B2 | Lipid compositions | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-11-11 | — | — | US | disclosed |
| US-20120128760-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120128760-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010129709-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953095-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM4E 4794/4885NPC1 13/4885 |
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM4E 4794/4885NPC1 13/4885 |
| US-20150190515-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM4E 4794/4885NPC1 13/4885 |
| US-10456473-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM4E 4794/4885NPC1 13/4885 |
| US-20120128760-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | HTR1A 4268/4885KDM4E 4740/4885NPC1 13/4885 |
| US-20240066129-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | HTR1A 4268/4885KDM4E 4740/4885NPC1 13/4885 |
| US-12023383-B2 | Lipid compositions | SGMS1, SGMS2, LIPA | HTR1A 4268/4885KDM4E 4740/4885NPC1 13/4885 |
| US-20200138955-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM4E 4794/4885NPC1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.